Funding Agency:
Alzheimer’s Drug Discovery Foundation

The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

The Prevention RFP supports:

  1. Studies of Cognitive Decline and Risk Reduction
  2. Comparative Effectiveness Research
  3. Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA)

Deadlines for Letters of Intent: Feb. 5, 2024; May 13, 2024; Sep. 30, 2024

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Amount Description

- Up to $5,000,000 for clinical trials based on stage and scope of research
- For studies requiring additional support, co-funding from other funding agencies or investors is encouraged
- Payment structure will be negotiated and based on milestone achievements and recruitment

Funding Type



Medical Fellow/Resident
Post Doctoral Fellows


Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2024